MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8426
-0.0973
-10.35%
After Hours: 0.8500 +0.0074 +0.88% 19:59 01/19 EST
OPEN
0.9280
PREV CLOSE
0.9399
HIGH
0.9280
LOW
0.8250
VOLUME
307.27K
TURNOVER
--
52 WEEK HIGH
8.16
52 WEEK LOW
0.8000
MARKET CAP
33.14M
P/E (TTM)
-0.7149
1D
5D
1M
3M
1Y
5Y
BRIEF-Oncosec Announces Changes To Board Of Directors
reuters.com · 12/17/2021 14:11
Caxton Corp Buys S&P 500 ETF TRUST ETF, iShares MSCI EAFE ETF, Elevation Oncology Inc, ...
GuruFocus News · 11/15/2021 19:38
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 11/12/2021 12:40
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Benzinga · 11/08/2021 13:24
BRIEF-OncoSec Medical Inc Files For Mixed Shelf Of Upto $100 Mln
reuters.com · 11/08/2021 11:16
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study
OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, M...
PR Newswire · 11/02/2021 12:00
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 10/21/2021 12:05
OncoSec Provides Business Update
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today anno...
PR Newswire · 10/20/2021 20:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of OncoSec Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONCS stock price target is 10.33 with a high estimate of 11.00 and a low estimate of 10.00.
High11.00
Average10.33
Low10.00
Current 0.8426
EPS
Actual
Estimate
-0.30-0.22-0.15-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 47
Institutional Holdings: 6.62M
% Owned: 16.83%
Shares Outstanding: 39.33M
TypeInstitutionsShares
Increased
12
812.66K
New
11
526.05K
Decreased
8
467.28K
Sold Out
14
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.06%
Pharmaceuticals & Medical Research
-0.76%
Key Executives
Chairman/Director
Linda Shi
Chief Accounting Officer/Vice President - Finance/Controller
Robert Delaversano
Vice President - Business Development
Joe Smith
Director
Joon Kim
Director
Kevin Smith
Director
Chao Zhou
Independent Director
James Demesa
Independent Director
Herbert Lyerly
No Data
About ONCS
OncoSec Medical Incorporated is a late-stage biotechnology company. The Company is focused on designing, developing and commercializing therapies and medical approaches for the treatment of cancer. Its core technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral electroporation (EP) delivery devices, such as the OncoSec Medical System (OMS) Electroporation device (OMS EP) device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its lead product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO), with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.